In the present study, differences in S100A8/S100A9 expression in the TME, reflective of shifts in the immunological composition of the TME could be detected in the very early course of therapy via in vivo imaging, when macroscopic differences in the form of tumor growth, which, therefore, would also be depictable via clinically established imaging methods, were not yet evident. This evidence concerns the gene S100A9 and neoplasm.